CHESTERBROOK, PA — Neuraptive Therapeutics has added former Lundbeck Chief Executive Ulf Wiinberg to its board of directors and appointed biotechnology finance executive William “Bill” MacKenzie as senior vice president of finance, moves that bolster the company’s leadership team as it advances its lead nerve repair therapy toward commercialization.
The appointments come as Neuraptive continues development of NTX-001, a product candidate targeting peripheral nerve injuries, and builds the operational infrastructure needed to support future commercial activities.
Wiinberg brings more than two decades of leadership experience in the pharmaceutical and biotechnology sectors. He most recently served as chief executive of X-Vax Technology from 2017 to 2024 and previously led Danish drugmaker Lundbeck from 2008 to 2014.
Before joining Lundbeck, Wiinberg held senior leadership roles at Wyeth, including worldwide president of its consumer healthcare division and president of the Europe, Middle East and Africa region before the company’s acquisition by Pfizer.
He currently serves on the boards of several healthcare and life sciences companies, including UCB, Alfa Laval, SIGRID Therapeutics and MiNK Therapeutics.
“I look forward to working collaboratively with my fellow directors and the management team at this exciting time in Neuraptive’s journey as the company continues to advance its important work to address the unmet needs of physicians and patients impacted by peripheral nerve injuries,” Wiinberg said.
MacKenzie, who has served as a finance consultant to Neuraptive since March 2025, will oversee the company’s finance organization and operational infrastructure development.
His background includes finance leadership roles at Sage Therapeutics, Prelude Therapeutics, LifeScan and Zyla Life Sciences. Neuraptive said his experience spans accounting, financial planning and analysis, commercial operations and research and development functions.
According to the company, MacKenzie has worked across public, private and private equity-backed organizations and has supported businesses through product launches and corporate restructuring efforts.
“Bill’s deep financial expertise and leadership will be instrumental as we continue to progress NTX-001 toward commercialization, while Ulf’s global industry experience and strategic insight will provide immense value to our Board and leadership team,” Chairman and Chief Executive Officer Bob Radie said.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.